Trial
NCT00581997
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Pulmonary Fibrosis Secondary to Systemic Sclerosis
Intervention
QAX576
Why stopped
Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-19